- Home
- FENG vs AKTX Comparison
FENG vs AKTX Comparison
Compare FENG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENG
- AKTX
- Stock Information
- Founded
- FENG 1998
- AKTX N/A
- Country
- FENG China
- AKTX United States
- Employees
- FENG N/A
- AKTX N/A
- Industry
- FENG Broadcasting
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- FENG Industrials
- AKTX Health Care
- Exchange
- FENG Nasdaq
- AKTX Nasdaq
- Market Cap
- FENG 32.7M
- AKTX 26.5M
- IPO Year
- FENG 2011
- AKTX N/A
- Fundamental
- Price
- FENG $2.80
- AKTX $1.02
- Analyst Decision
- FENG
- AKTX Strong Buy
- Analyst Count
- FENG 0
- AKTX 2
- Target Price
- FENG N/A
- AKTX $3.30
- AVG Volume (30 Days)
- FENG 22.5K
- AKTX 467.2K
- Earning Date
- FENG 11-11-2025
- AKTX 11-18-2025
- Dividend Yield
- FENG N/A
- AKTX N/A
- EPS Growth
- FENG N/A
- AKTX N/A
- EPS
- FENG N/A
- AKTX N/A
- Revenue
- FENG $101,168,374.00
- AKTX N/A
- Revenue This Year
- FENG N/A
- AKTX N/A
- Revenue Next Year
- FENG N/A
- AKTX N/A
- P/E Ratio
- FENG N/A
- AKTX N/A
- Revenue Growth
- FENG 5.53
- AKTX N/A
- 52 Week Low
- FENG $1.28
- AKTX $0.57
- 52 Week High
- FENG $3.65
- AKTX $3.70
- Technical
- Relative Strength Index (RSI)
- FENG 55.74
- AKTX 55.06
- Support Level
- FENG $2.70
- AKTX $0.90
- Resistance Level
- FENG $2.80
- AKTX $1.24
- Average True Range (ATR)
- FENG 0.17
- AKTX 0.14
- MACD
- FENG -0.02
- AKTX 0.02
- Stochastic Oscillator
- FENG 22.02
- AKTX 53.70
About FENG Phoenix New Media Limited
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.